Gulati S C, Romero C E, Ciavarella D
Department of Medicine, New York Hospital-Cornell Medical Center, New York.
Oncology (Williston Park). 1994 Sep;8(9):19-24; discussion 24, 29-32.
Although the role of hematopoietic stem-cell transplantation (HSCT) in cancer treatment is rapidly expanding, decreasing the side effects of stem-cell infusion is a major challenge. Cancer cells present in the stem-cell collection can cause relapse after autologous transplantation. In allogeneic transplantation. T lymphocytes contribute to graft-versus-host disease. Various methods of purging have been used to remove these unwanted cells, and there is some evidence that such manipulations are clinically useful. Nevertheless, the inability to detect minimal disease makes it difficult to determine whether relapse is caused by incomplete disease eradication in the patient or by the infused cells. This makes it hard to justify the clinical benefit of ex vivo purging. Researchers can focus on this issue by designing studies with minimal variation in other factors that affect the success of stem-cell transplantation.
尽管造血干细胞移植（HSCT）在癌症治疗中的作用正在迅速扩大，但降低干细胞输注的副作用仍是一项重大挑战。干细胞采集中存在的癌细胞可导致自体移植后复发。在异基因移植中，T淋巴细胞会引发移植物抗宿主病。已采用多种清除方法来去除这些不需要的细胞，并且有一些证据表明此类操作在临床上是有用的。然而，由于无法检测到微小疾病，因此难以确定复发是由患者体内疾病根除不完全还是由输注的细胞引起的。这使得难以证明体外清除的临床益处。研究人员可以通过设计其他影响干细胞移植成功的因素变化最小的研究来关注这个问题。
